Taro Pharmaceutical Industries Ltd.
TARO
TARO was delisted on the 21st of June, 2024.
69 hedge funds and large institutions have $197M invested in Taro Pharmaceutical Industries Ltd. in 2022 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 22 increasing their positions, 27 reducing their positions, and 7 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 7
3% less funds holding
Funds holding: 71 → 69 (-2)
15% less capital invested
Capital invested by funds: $231M → $197M (-$34.6M)
19% less repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 27
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $15K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Ameriprise
Minneapolis,
Minnesota
|
+$3.34M |
| 2 |
EP
Eversept Partners
New York
|
+$1.83M |
| 3 |
Hotchkis & Wiley Capital Management
Los Angeles,
California
|
+$1.63M |
| 4 |
BIP
Brandes Investment Partners
La Jolla,
California
|
+$1.38M |
| 5 |
KAM
Krensavage Asset Management
New York
|
+$1.26M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$5.85M |
| 2 |
Northern Trust
Chicago,
Illinois
|
-$2.4M |
| 3 |
Invesco
Atlanta,
Georgia
|
-$2.02M |
| 4 |
Renaissance Technologies
New York
|
-$827K |
| 5 |
MGP
Metis Global Partners
San Diego,
California
|
-$766K |
TARO Hedge Fund Activity: Q1 2022 in Review
69 of the 6,341 institutional investors tracked by Wall St. Rank reported a position in Taro Pharmaceutical Industries Ltd. (TARO) for Q1 2022, worth a combined $197M — down 15% from $231M a quarter earlier.
Fund positioning in TARO was balanced in Q1 2022: 7 funds opened new positions, 7 closed out, 22 added to existing stakes and 27 trimmed.
The largest buyer was Ameriprise, adding an estimated $3.34M. The largest seller was Fidelity Investments, cutting an estimated $5.85M.
- 69 institutional investors held Taro Pharmaceutical Industries Ltd. (TARO) as of Q1 2022, down from 71 in Q4 2021.
- Funds reported $197M of Taro Pharmaceutical Industries Ltd. stock for Q1 2022, down 15% quarter-over-quarter.
- 7 funds opened new Taro Pharmaceutical Industries Ltd. positions in Q1 2022 and 7 closed out, a net change of 0 holders.
- The largest Taro Pharmaceutical Industries Ltd. buyer in Q1 2022 was Ameriprise, an estimated $3.34M added.
- The largest Taro Pharmaceutical Industries Ltd. seller in Q1 2022 was Fidelity Investments, an estimated $5.85M sold.
Based on aggregated 13F filings for Q1 2022.